144 related articles for article (PubMed ID: 9007701)
1. Impairment of growth hormone responsiveness to growth hormone releasing hormone and pyridostigmine in patients affected by Prader-Labhardt-Willi syndrome.
Beccaria L; Benzi F; Sanzari A; Bosio L; Brambilla P; Chiumello G
J Endocrinol Invest; 1996 Nov; 19(10):687-92. PubMed ID: 9007701
[TBL] [Abstract][Full Text] [Related]
2. Growth hormone (GH) response to combined pyridostigmine and GH-releasing hormone administration in patients with Prader-Labhard-Willi syndrome.
Cappa M; Grossi A; Borrelli P; Ghigo E; Bellone J; Benedetti S; Carta D; Loche S
Horm Res; 1993; 39(1-2):51-5. PubMed ID: 8406340
[TBL] [Abstract][Full Text] [Related]
3. Reduced growth hormone (GH) responsiveness to combined GH-releasing hormone and pyridostigmine administration in the Prader-Willi syndrome.
Grugni G; Guzzaloni G; Moro D; Bettio D; De Medici C; Morabito F
Clin Endocrinol (Oxf); 1998 Jun; 48(6):769-75. PubMed ID: 9713567
[TBL] [Abstract][Full Text] [Related]
4. GH secretion in Prader-Labhard-Willi syndrome: somatotrope responsiveness to GHRH is enhanced by arginine but not by pyridostigmine.
Beccaria L; Bosio L; Sanzari A; Aimaretti G; Ghigo E; Chiumello G
J Pediatr Endocrinol Metab; 1996; 9(6):577-83. PubMed ID: 9004172
[TBL] [Abstract][Full Text] [Related]
5. Impairment of GH responsiveness to GH-releasing hexapeptide (GHRP-6) in Prader-Willi syndrome.
Grugni G; Guzzaloni G; Morabito F
J Endocrinol Invest; 2001 May; 24(5):340-8. PubMed ID: 11407654
[TBL] [Abstract][Full Text] [Related]
6. Effect of central cholinergic neurotransmission enhancement by pyridostigmine on the growth hormone secretion elicited by clonidine, arginine, or hypoglycemia in normal and obese subjects.
Cordido F; Dieguez C; Casanueva FF
J Clin Endocrinol Metab; 1990 May; 70(5):1361-70. PubMed ID: 2159483
[TBL] [Abstract][Full Text] [Related]
7. Cholinergic receptor activation by pyridostigmine restores growth hormone (GH) responsiveness to GH-releasing hormone administration in obese subjects: evidence for hypothalamic somatostatinergic participation in the blunted GH release of obesity.
Cordido F; Casanueva FF; Dieguez C
J Clin Endocrinol Metab; 1989 Feb; 68(2):290-3. PubMed ID: 2493023
[TBL] [Abstract][Full Text] [Related]
8. Cholinergic modulation of growth hormone responses to growth hormone-releasing hormone in uraemic patients on peritoneal dialysis.
Díez JJ; Iglesias P; Selgas R; Bajo MA; Aguilera A
Clin Endocrinol (Oxf); 2000 Nov; 53(5):587-93. PubMed ID: 11106919
[TBL] [Abstract][Full Text] [Related]
9. Growth hormone response to standard provocative stimuli and combined tests in very young children with Prader-Willi syndrome.
Di Giorgio G; Grugni G; Fintini D; Bocchini S; Spera S; Cuttini M; Cappa M; Crinò A
Horm Res Paediatr; 2014; 81(3):189-95. PubMed ID: 24503962
[TBL] [Abstract][Full Text] [Related]
10. The enhancing effect of pyridostigmine on the GH response to GHRH undergoes an accelerated age-related reduction in Down syndrome.
Arvat E; Gianotti L; Ragusa L; Valetto MR; Cappa M; Aimaretti G; Ramunni J; Grottoli S; Camanni F; Ghigo E
Dementia; 1996; 7(5):288-92. PubMed ID: 8872421
[TBL] [Abstract][Full Text] [Related]
11. Comparison of growth hormone-releasing effect of growth hormone-releasing hormone, clonidine and pyridostigmine in normal children and adolescents. GH-releasing effect of GHRH, clonidine and pyridostigmine.
Ghigo E; Arvat E; Nicolosi M; Mazza E; Camanni F
Panminerva Med; 1990; 32(1):1-3. PubMed ID: 2263395
[TBL] [Abstract][Full Text] [Related]
12. Impairment of GH responsiveness to combined GH-releasing hormone and arginine administration in adult patients with Prader-Willi syndrome.
Grugni G; Marzullo P; Ragusa L; Sartorio A; Trifirò G; Liuzzi A; Crinò A;
Clin Endocrinol (Oxf); 2006 Oct; 65(4):492-9. PubMed ID: 16984242
[TBL] [Abstract][Full Text] [Related]
13. Growth hormone responses to growth hormone-releasing hormone and clonidine before and after erythropoietin therapy in CAPD patients.
Díez J; Iglesias P; Sastre J; Méndez J; Selgas R; Gómez-Pan A
Nephron; 1996; 74(3):548-54. PubMed ID: 8938679
[TBL] [Abstract][Full Text] [Related]
14. Evidence that alpha 2-adrenergic pathways play a major role in growth hormone (GH) neuroregulation: alpha 2-adrenergic agonism counteracts the inhibitory effect of muscarinic cholinergic receptor blockade on the GH response to GH-releasing hormone, while alpha 2-adrenergic blockade diminishes the potentiating effect of increased cholinergic tone on such stimulation in normal men.
Devesa J; Diaz MJ; Tresguerres JA; Arce V; Lima L
J Clin Endocrinol Metab; 1991 Aug; 73(2):251-6. PubMed ID: 1677361
[TBL] [Abstract][Full Text] [Related]
15. Differences in reproducibility and peak growth hormone responses to repeated testing with various stimulators in healthy adults.
Hoeck HC; Jakobsen PE; Vestergaard P; Falhof J; Laurberg P
Growth Horm IGF Res; 1999 Feb; 9(1):18-24. PubMed ID: 10207504
[TBL] [Abstract][Full Text] [Related]
16. GH/IGF-I axis in Prader-Willi syndrome: evaluation of IGF-I levels and of the somatotroph responsiveness to various provocative stimuli. Genetic Obesity Study Group of Italian Society of Pediatric Endocrinology and Diabetology.
Corrias A; Bellone J; Beccaria L; Bosio L; Trifirò G; Livieri C; Ragusa L; Salvatoni A; Andreo M; Ciampalini P; Tonini G; Crinò A
J Endocrinol Invest; 2000 Feb; 23(2):84-9. PubMed ID: 10800760
[TBL] [Abstract][Full Text] [Related]
17. Pyridostigmine enhances, but does not normalise, the GH response to GH-releasing hormone in obese subjects.
Castro RC; Vieira JG; Chacra AR; Besser GM; Grossman AB; Lengyel AM
Acta Endocrinol (Copenh); 1990 Mar; 122(3):385-90. PubMed ID: 2109445
[TBL] [Abstract][Full Text] [Related]
18. GHRH plus arginine and arginine administration evokes the same ratio of GH isoforms levels in young patients with Prader-Willi syndrome.
Rigamonti AE; Crinò A; Bocchini S; Convertino A; Bidlingmaier M; Haenelt M; Tamini S; Cella SG; Grugni G; Sartorio A
Growth Horm IGF Res; 2018 Apr; 39():13-18. PubMed ID: 29217318
[TBL] [Abstract][Full Text] [Related]
19. Different effects of pyridostigmine on growth hormone (GH) response to GH-releasing hormone in endogenous and exogenous hypercortisolemic patients.
Borges MH; Castro RC; Kater CE; Lengyel AM
Braz J Med Biol Res; 1993 Nov; 26(11):1191-200. PubMed ID: 7907904
[TBL] [Abstract][Full Text] [Related]
20. Unaltered ratio of circulating levels of growth hormone/GH isoforms in adults with Prader-Willi syndrome after GHRH plus arginine administration.
Rigamonti AE; Grugni G; Marazzi N; Bini S; Bidlingmaier M; Sartorio A
Growth Horm IGF Res; 2015 Aug; 25(4):168-73. PubMed ID: 26059749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
